NovellusDx Cancer Early Detection Blood Test- Clinical Trial

Assessing the Ability of An Innovative Screening Method To Identify Proteomic Changes In Cancer Patients- Protocol

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01883388

Enrollment

Registered

2013-06-21

Start date

2013-06-30

Completion date

Unknown

Last updated

2018-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Keywords

Lung Cancer, blood sample

Brief summary

NovellusDx early detection test is a simple to perform blood test, which identifies the deregulated signaling pathways within the patient tumor based on protein secretion to the blood, thus enabling early stage disease signature detection. The investigators' current clinical trial is focused on proving the main feature of NovellusDx's Early Detection Test- discriminating between cancer patients and healthy subjects.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* subjects ages 18 and above ICF obtain

Exclusion criteria

* none

Design outcomes

Primary

Measure	Time frame	Description
Number of Participants with a significant cancer fingerprint as measured by NovellusDX Cancer Early Detection test	3.5 years	NovellusDX Cancer Early Detection test will identify participants with significant cancer fingerprint based on tumor protein secretion to the blood circulation in sick subjects.

Countries

Israel

Outcome results